BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

575 related articles for article (PubMed ID: 8646677)

  • 41. Role of free radicals in an adriamycin-resistant human small cell lung cancer cell line.
    Meijer C; Mulder NH; Timmer-Bosscha H; Zijlstra JG; de Vries EG
    Cancer Res; 1987 Sep; 47(17):4613-7. PubMed ID: 3040227
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
    Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
    Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
    Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin.
    Yang CZ; Luan FJ; Xiong DS; Liu BR; Xu YF; Gu KS
    Zhongguo Yao Li Xue Bao; 1995 Jul; 16(4):333-7. PubMed ID: 7668104
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Phase II study of lung cancer--evaluation of new drug in small cell lung cancer (SCLC) and phase II testing of analogues].
    Furuse K
    Gan To Kagaku Ryoho; 1991 Jul; 18(9):1499-503. PubMed ID: 1649580
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of several resistance mechanisms in untreated human kidney and lung carcinomas.
    Volm M; Mattern J; Efferth T; Pommerenke EW
    Anticancer Res; 1992; 12(4):1063-7. PubMed ID: 1354430
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of acquired resistance to cis-diamminedichloroplatinum (II) in BE human colon carcinoma cells.
    Fram RJ; Woda BA; Wilson JM; Robichaud N
    Cancer Res; 1990 Jan; 50(1):72-7. PubMed ID: 2293559
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin.
    Mirski SE; Gerlach JH; Cole SP
    Cancer Res; 1987 May; 47(10):2594-8. PubMed ID: 2436751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein.
    Doyle LA; Ross DD; Ordonez JV; Yang W; Gao Y; Tong Y; Belani CP; Gutheil JC
    Br J Cancer; 1995 Sep; 72(3):535-42. PubMed ID: 7669558
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
    Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
    Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
    Friche E; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of response to the DNA topoisomerase II inhibitors doxorubicin and etoposide in human lung cancer cell lines.
    Kasahara K; Fujiwara Y; Sugimoto Y; Nishio K; Tamura T; Matsuda T; Saijo N
    J Natl Cancer Inst; 1992 Jan; 84(2):113-8. PubMed ID: 1310509
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Podophyllotoxin analogs: effects on DNA topoisomerase II, tubulin polymerization, human tumor KB cells, and their VP-16-resistant variants.
    Liu SY; Hwang BD; Haruna M; Imakura Y; Lee KH; Cheng YC
    Mol Pharmacol; 1989 Jul; 36(1):78-82. PubMed ID: 2546053
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Establishment and characterization of an etoposide-resistant human small cell lung cancer cell line.
    Takigawa N; Ohnoshi T; Ueoka H; Kiura K; Kimura I
    Acta Med Okayama; 1992 Jun; 46(3):203-12. PubMed ID: 1354408
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).
    Seeber S; Osieka R; Schmidt CG; Achterrath W; Crooke ST
    Cancer Res; 1982 Nov; 42(11):4719-25. PubMed ID: 6889912
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interaction of recombinant human tumor necrosis factor and etoposide in human lung cancer cell lines.
    Doyle LA; Hamburger AW; Goldstein LH; Park HJ
    Mol Biother; 1990 Sep; 2(3):169-74. PubMed ID: 2171561
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance of in vitro grown IgM immunocytoma cells to cis-diamminedichloroplatinum (II) (cis-DDP) and cross-resistance to other DNA interacting drugs.
    Vendrik CP; de Jong WH; Van der Minnen AC; Fichtinger-Schepman AM; Steerenberg PA; Schornagel JH
    Anticancer Res; 1990; 10(2A):447-52. PubMed ID: 2346318
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II).
    Rosowsky A; Wright JE; Cucchi CA; Flatow JL; Trites DH; Teicher BA; Frei E
    Cancer Res; 1987 Nov; 47(22):5913-8. PubMed ID: 3664492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors.
    Wolverton JS; Danks MK; Granzen B; Beck WT
    Cancer Res; 1992 Aug; 52(15):4248-53. PubMed ID: 1322239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.